The Timing Hypothesis: Why When You Start HRT May Matter More Than Whether You Start

Published in Circulation in February 2023, this review from a multidisciplinary panel — including cardiologists, gynecologists, and endocrinologists convened through the American College of Cardiology — reexamines the timing hypothesis for menopausal hormone therapy. The core argument: estrogen's effects on the cardiovascular system are not uniform. When initiated early, within 10 years of menopause or before age 60, hormone therapy appears to exert protective effects on healthy endothelium. When initiated later, in women with established atherosclerotic plaque, the same therapy may destabilize plaques and increase cardiovascular events.

The review synthesizes evidence from randomized controlled trials, imaging studies, and observational data to make the case that the WHI results — which enrolled women with a mean age of 63 — should not be applied uniformly to symptomatic women in early menopause. The data support a window of opportunity in which hormone therapy can reduce all-cause mortality and cardiovascular risk, provided it is started before age 60 or within 10 years of menopause and continued for six or more years. The paper also addresses formulation differences, noting that transdermal estrogen and micronized progesterone carry lower thrombotic risk than the oral conjugated estrogens and medroxyprogesterone studied in the WHI.

Why This Matters

The timing hypothesis reframes hormone therapy from a binary risk-benefit calculation into a time-sensitive clinical decision. This has direct implications for symptom tracking and health monitoring. Women in early perimenopause or recently postmenopausal have a different risk-benefit profile than women a decade past their final period. Knowing precisely when symptoms began, how they have progressed, and when menopause occurred is not academic detail — it is clinically actionable information that determines whether hormone therapy is likely to help or harm. Platforms that track cycle patterns, vasomotor symptoms, and biomarker trends over time give women and their clinicians the longitudinal data needed to make this decision with confidence rather than guesswork.